US2003186406A1PendingUtilityA1

Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide

49
Assignee: AJINOMOTO KKPriority: Sep 29, 1995Filed: Jan 8, 2002Published: Oct 2, 2003
Est. expirySep 29, 2015(expired)· nominal 20-yr term from priority
Inventors:Kokichi KikuchiNoriyuki SatoHiromitsu SaharaTakahiro YasojimaYoshimasa WadaManabu SuzukiJunji Hamuro
A61P 35/00A61P 43/00A61P 37/00A61P 1/00C07H 21/04C07K 14/4748C07K 7/06A61K 38/00C07K 14/705A61K 39/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A peptide that induces CTL against human gastric cancer cells is provided. A peptide having a specific amino-acid sequence and induces cytotoxic T cells that targets gastric cancer cells may be used as an agent for preventing or treating gastric cancer.

Claims

exact text as granted — not AI-modified
What is claimed as new and desired to be secured by Letters Patent of the United States is:  
     
         1 . A peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         2 . The peptide of  claim 1 , wherein the HLA molecule is HLA-A31.  
     
     
         3 . The peptide of  claim 1 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.  
     
     
         4 . The peptide of  claim 1 , which has an amino-acid sequence obtained by modifying the amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing in order that said peptide can induce more efficiently the cytotoxic T cell that targets the gastric cancer cell.  
     
     
         5 . The peptide of  claim 4  which has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.  
     
     
         6 . A composition for preventing or treating human gastric cancer, said composition containing a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets the gastric cancer cell.  
     
     
         7 . The composition of  claim 6 , wherein the HLA molecule is HLA-A31.  
     
     
         8 . The composition of  claim 6 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.  
     
     
         9 . The composition of  claim 6 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.  
     
     
         10 . A DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         11 . The DNA of  claim 10 , wherein the HLA molecule is HLA-A31.  
     
     
         12 . The DNA of  claim 10 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.  
     
     
         13 . The DNA of  claim 10 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.  
     
     
         14 . A vaccine for preventing or treating human gastric cancer, said vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         15 . The vaccine of  claim 14 , wherein the HLA molecule is HLA-A31.  
     
     
         16 . The vaccine of  claim 14 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.  
     
     
         17 . The vaccine of  claim 14 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.  
     
     
         18 . A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         19 . A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of CTL which have been activated with a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         20 . A method for preventing or treating gastric cancer, comprising administering to a patient in need thereof an effective amount of a vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.

Join the waitlist — get patent alerts

Track US2003186406A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.